This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution
by Zacks Equity Research
CeriBell gains FDA clearance for its continuous delirium monitoring solution, boosting its AI-driven EEG platform and expanding its role in critical care.
BSXPositive Net Change ATRCPositive Net Change PAHCNegative Net Change CBLLNegative Net Change
medical medical-devices
Should You Buy Southern Missouri Bancorp (SMBC) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
SMBCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hims & Hers Expands Weight-Management Program to the United Kingdom
by Zacks Equity Research
HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to obesity treatments.
BSXPositive Net Change ISRGNegative Net Change MEDPPositive Net Change HIMSPositive Net Change
medical medical-devices
What Is Driving Hologic's Strength in the US Diagnostics Market?
by Moumi Mondal
HOLX's Diagnostics gains accelerate as U.S. molecular testing drives growth and new Panther Fusion and Genius platform approvals widen its runway.
ABTPositive Net Change RHHBYNegative Net Change HOLXPositive Net Change
medical medical-devices
Hims & Hers Expands Its Technology-Driven Personalized Virtual Care
by Debanjana Dey
HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.
TDOCPositive Net Change HIMSPositive Net Change DOCSPositive Net Change
medical medical-devices
ISRG Gets FDA Clearance to Use da Vinci SP Robot for General Surgeries
by Zacks Equity Research
Intuitive Surgical broadens its da Vinci SP system with FDA clearance for three new surgeries, expanding its role in minimally invasive care.
ISRGNegative Net Change EDAPNo Net Change VCYTNegative Net Change AORTNegative Net Change
medical medical-devices
First Financial Bancorp (FFBC) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
FFBCNo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Can Intuitive Surgical Weather GLP-1 Drag on Bariatric Surgery?
by Indrajit Bandyopadhyay
Intuitive Surgical grapples with a GLP-1-driven bariatric slump but leans on strong general surgery gains and rising da Vinci 5 adoption.
MDTPositive Net Change ISRGNegative Net Change TFXPositive Net Change
medical medical-devices
Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now
by Zacks Equity Research
WST leans on strong HVP demand, rising GLP-1 exposure and Annex 1 tailwinds, even as pricing and device margins weigh on near-term performance.
BSXPositive Net Change ISRGNegative Net Change WSTNegative Net Change MEDPPositive Net Change
medical medical-devices
Should You Continue to Hold EW Stock in Your Portfolio?
by Zacks Equity Research
Edwards Lifesciences leans on growth in Surgical Structural Heart, TAVR and TMTT, though macro pressures and litigation continue to weigh on margins.
EWNegative Net Change ILMNNegative Net Change PODDPositive Net Change BTSGPositive Net Change
medical medical-devices
Boston Scientific Sustains Momentum in the PFA Market: What's Next?
by Moumi Mondal
BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.
ABTPositive Net Change BSXPositive Net Change MDTPositive Net Change
medical medical-devices
BEAT Secures FDA Nod for First Cable-Free At-Home 12-Lead ECG System
by Zacks Equity Research
HeartBeam's FDA clearance for its cable-free at-home 12-lead ECG marks a pivotal step toward commercialization and broader cardiac-care adoption.
BSXPositive Net Change ISRGNegative Net Change BEATPositive Net Change MEDPPositive Net Change
medical medical-devices
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
by Zacks Equity Research
FMS's acquisitions, partnerships and global reach fuel growth, even as rising costs and optimization efforts weigh on near-term performance.
BSXPositive Net Change ISRGNegative Net Change FMSPositive Net Change MEDPPositive Net Change
medical medical-devices
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor
by Zacks Equity Research
Pulse Biosciences partners with MD Anderson to study its nPulse technology for treating benign and malignant thyroid tumors upon receiving FDA approval for a first-in-human trial.
ISRGNegative Net Change VCYTNegative Net Change PLSEPositive Net Change AORTNegative Net Change
medical medical-devices
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
Cencora's U.S. Healthcare Solutions strength, RCA gains, and raised FY25 guidance underscore its accelerating growth momentum.
ISRGNegative Net Change CORPositive Net Change VCYTNegative Net Change MEDPPositive Net Change
medical medical-devices
Is it Worth Retaining NEOG Stock in Your Portfolio for Now?
by Zacks Equity Research
Neogen leans on new product launches and 3M Food Safety integration to offset solvency strains and macro pressures.
OMCLNegative Net Change ILMNNegative Net Change NEOGNegative Net Change BTSGPositive Net Change
medical medical-devices
Phibro Animal Health Stock Climbs 59.6% YTD: What's Driving It?
by Zacks Equity Research
PAHC's 59% YTD surge rides on strong Animal Health momentum, booming vaccines and global gains despite the rising competition.
OMCLNegative Net Change ILMNNegative Net Change PAHCNegative Net Change BTSGPositive Net Change
medical medical-devices
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX gains momentum as OCS technology, a robust pipeline and strong Q3 results fuel growth, though gross margin pressure tempers the outlook.
BSXPositive Net Change ISRGNegative Net Change MEDPPositive Net Change TMDXPositive Net Change
medical medical-devices
Hims & Hers Plunges 29.1% in 6 Months: Time to Hold the Stock or Sell?
by Debanjana Dey
HIMS expands into Canada and Europe while facing regulatory hurdles and execution risks in weight-loss care.
TDOCPositive Net Change GDRXPositive Net Change HIMSPositive Net Change
medical medical-devices
Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run?
by Urmimala Biswas
Tempus AI rallies in 2025, but a Hold rank and mixed style scores argue for patience until pricing, FDA, and MRD milestones firm up.
IQVNegative Net Change GHPositive Net Change TEMNegative Net Change
artificial-intelligence earnings-report healthcare medical medical-devices valuation
Should You Buy Alpine Income (PINE) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
PINENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
CARL Launches Aprevo Cervical Platform for Personalized Spine Surgery
by Zacks Equity Research
Carlsmed launches personalized aprevo cervical platform with early cases and new reimbursement support driving momentum in spine surgery.
ISRGNegative Net Change MEDPPositive Net Change CARLNegative Net Change
medical medical-devices
Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now
by Zacks Equity Research
OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.
BSXPositive Net Change ISRGNegative Net Change OPKPositive Net Change MEDPPositive Net Change
medical medical-devices
RMD Stock Set to Gain From FDA Clearance of AI-Enabled Smart Comfort
by Zacks Equity Research
Resmed gains FDA's nod for Smart Comfort, an AI-driven CPAP tool boosting sleep therapy personalization and adherence.
OMCLNegative Net Change ILMNNegative Net Change RMDNegative Net Change BTSGPositive Net Change
medical medical-devices
CONMED Stock Falls as It Strategically Exits Gastroenterology Portfolio
by Zacks Equity Research
CNMD is set to exit its gastroenterology portfolio to streamline its focus on higher-growth surgical platforms and boost long-term margins.
BSXPositive Net Change CNMDNegative Net Change ISRGNegative Net Change MEDPPositive Net Change
medical medical-devices